patient subgroup...
age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) beta variant (B.1.351 / 501Y.V2, South Africa) delta variant (B.1.617.2, Indian) elderly (typically over 65yr)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) - versus potential COVID-19 treatments - for COVID-19 prophylaxis (excluding children)
pdf
xlsx
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 deaths 0.20 [0.02, 1.72]< 1 0% 1 study (1/-) 92.8 % NA not evaluable crucial - symptomatic Covid-19 0.29 [0.21, 0.39]< 1 65% 2 studies (2/-) 100.0 % low not evaluable high important - asymptomatic COVID case 0.33 [0.23, 0.48]< 1 0% 1 study (1/-) 100.0 % NA not evaluable non important - infection (PCR positive symptomatic or not) 0.44 [0.33, 0.59]< 1 0% 1 study (1/-) 100.0 % NA not evaluable non important - severe COVID-19 occurrence 0.49 [0.02, 14.54]< 1 0% 1 study (1/-) 65.9 % NA not evaluable non important - vaccine efficacy after dose 1 (and before dose 2) 0.24 [0.14, 0.41]< 1 0% 1 study (1/-) 100.0 % NA not evaluable non important - safety endpoints 00 serious adverse events 0.86 [0.64, 1.17]< 1 0% 1 study (1/-) 82.5 % NA not evaluable important - adverse events 1.37 [1.07, 1.74]< 1 60% 4 studies (4/-) 0.6 % NA not evaluable non important - ATE (Myocardial infarction or ischemic stroke) 0.39 [0.14, 1.06]< 1 0% 2 studies (2/-) 96.8 % NA not evaluable non important - Guillain-Barré syndrome 1.00 [0.03, 29.81]< 1 0% 1 study (1/-) 50.0 % NA not evaluable non important - intracranial hemorrhage 0.65 [0.12, 3.39]< 1 0% 5 studies (5/-) 69.6 % NA not evaluable non important - ischemic stroke 0.44 [0.11, 1.76]< 1 0% 5 studies (5/-) 87.8 % NA not evaluable non important - Myocardial infarction 0.57 [0.14, 2.31]< 1 0% 5 studies (5/-) 78.3 % NA not evaluable non important - pulmonary embolism 0.81 [0.15, 4.42]< 1 0% 5 studies (5/-) 59.7 % NA not evaluable non important - serious adverse events (SAE), any 0.87 [0.71, 1.06]< 1 0% 3 studies (3/-) 91.6 % NA not evaluable non important - venous thromboembolism 0.70 [0.07, 6.90]< 1 0% 2 studies (2/-) 62.0 % NA not evaluable non important - AE of interest endpoints 00 Bell's palsy 0.98 [0.23, 4.17]< 1 0% 2 studies (2/-) 51.1 % some concern not evaluable moderate non important - immediate allergic reaction 1.95 [0.07, 58.15]< 1 0% 1 study (1/-) 35.2 % NA not evaluable non important - multiple sclerosis 1.95 [0.07, 58.15]< 1 0% 1 study (1/-) 35.2 % NA not evaluable non important - myelitis 1.95 [0.18, 21.52]< 1 0% 1 study (1/-) 29.4 % NA not evaluable non important - Potential Immune Gastrointestinal disorders 0.33 [0.03, 3.13]< 1 0% 1 study (1/-) 83.3 % NA not evaluable non important - Potential Immune Musculoskeletal disorders 0.98 [0.06, 15.60]< 1 0% 1 study (1/-) 50.7 % NA not evaluable non important - Potential Immune Neuroinflammatory disorders 1.22 [0.33, 4.54]< 1 0% 1 study (1/-) 38.4 % NA not evaluable non important - Potential Immune Skin disorders 0.73 [0.16, 3.27]< 1 0% 1 study (1/-) 65.8 % NA not evaluable non important - Potential Immune Vasculitides 0.49 [0.02, 14.54]< 1 0% 1 study (1/-) 65.9 % NA not evaluable non important - Thromboembolic events 0.49 [0.15, 1.62]< 1 0% 1 study (1/-) 87.9 % NA not evaluable non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.